Search research articles
Contact Us
Filters
Showing results (61-70 of 88) with videos related to
Page
of 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2020
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by <i>ROS1</i> Fusions
Hiroki Sato, Adam J Schoenfeld, Evan Siau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 19, 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers
Alexander Drilon, Jessica J Lin, Thomas Filleron, et al.
Future Oncology (London, England)
|
March 30, 2026
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2020
<i>MET</i> Exon 14-altered Lung Cancers and MET Inhibitor Resistance
Robin Guo, Michael Offin, A Rose Brannon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2023
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With
Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2024
Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Monica F Chen, Soo-Ryum Yang, Jessica J Tao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 31, 2026
Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Non-Squamous Non-Small Cell Lung Cancer Treated with Chemoradiation and Immunotherapy
Nikhil P Mankuzhy, Valentina Santo, Jacob Y Shin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 19, 2025
Clinical Significance of MTAP Deletions and their Overlap with Concurrent Oncogenic Driver Alterations Including EGFR in Non-Small Cell Lung Cancer
Jessica S Ross, Rohit Thummalapalli, Christopher A Febres-Aldana, et al.
Future Oncology (London, England)
|
February 15, 2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer
Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 88) with videos related to
Sort By:
Page
of 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2020
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by <i>ROS1</i> Fusions
Hiroki Sato, Adam J Schoenfeld, Evan Siau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 19, 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers
Alexander Drilon, Jessica J Lin, Thomas Filleron, et al.
Future Oncology (London, England)
|
March 30, 2026
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2020
<i>MET</i> Exon 14-altered Lung Cancers and MET Inhibitor Resistance
Robin Guo, Michael Offin, A Rose Brannon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2023
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With
Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2024
Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Monica F Chen, Soo-Ryum Yang, Jessica J Tao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 31, 2026
Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Non-Squamous Non-Small Cell Lung Cancer Treated with Chemoradiation and Immunotherapy
Nikhil P Mankuzhy, Valentina Santo, Jacob Y Shin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 19, 2025
Clinical Significance of MTAP Deletions and their Overlap with Concurrent Oncogenic Driver Alterations Including EGFR in Non-Small Cell Lung Cancer
Jessica S Ross, Rohit Thummalapalli, Christopher A Febres-Aldana, et al.
Future Oncology (London, England)
|
February 15, 2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer
Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Page
of 9